ASGE

Dr. Neil Sharma Joins Peak Gastroenterology Associates in Colorado Springs

Retrieved on: 
Monday, January 8, 2024

Peak Gastroenterology Associates (“Peak” or “the Company”), the largest provider of gastroenterology and related ancillary diagnostic and therapeutic services in Colorado, today welcomed Neil Sharma, MD, one of the nation’s leading board-certified, fellowship-trained interventional gastroenterologists and endoscopists.

Key Points: 
  • Peak Gastroenterology Associates (“Peak” or “the Company”), the largest provider of gastroenterology and related ancillary diagnostic and therapeutic services in Colorado, today welcomed Neil Sharma, MD, one of the nation’s leading board-certified, fellowship-trained interventional gastroenterologists and endoscopists.
  • Dr. Sharma will lead Peak’s interventional program in Colorado Springs, Colorado.
  • Dr. Sharma joins Peak from Parkview Health, northeast Indiana’s largest not-for-profit healthcare provider, where he served for over 10 years, most recently as the first President of the Parkview Cancer Institute, which he helped to conceive and develop.
  • He went on to pursue an additional fellowship in Interventional Endoscopy at the University of North Carolina, Chapel Hill.

New study shows that WATS3D increases diagnostic yield of dysplasia in Barrett's esophagus, regardless of segment length

Retrieved on: 
Wednesday, August 2, 2023

Regardless of segment length, WATS3D is highly effective at increasing the diagnostic yield of intestinal metaplasia and dysplasia.

Key Points: 
  • Regardless of segment length, WATS3D is highly effective at increasing the diagnostic yield of intestinal metaplasia and dysplasia.
  • "WATS3D has previously shown diagnostic effectiveness for patients with known or suspected BE," said the lead author of the study, Dr. Arvind Trindade, Regional Director of Endoscopy, Northwell Health.
  • "This new study focuses on WATS3D performance in short versus long segment esophageal columnar-lined mucosa."
  • The adjunctive and absolute yields of WATS3D were calculated according to the length of the patient's BE segment.

Palatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference

Retrieved on: 
Tuesday, May 9, 2023

CRANBURY, N.J., May 9, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the presentation of the poster "Efficacy of the Melanocortin Receptor Agonist PL8177 as a Potential Therapy for Gastrointestinal Inflammatory Diseases" at the Digestive Disease Week annual meeting May 6-9, 2023 in Chicago, Illinois. The poster was presented by John Dodd, Ph.D., Senior Vice President of Preclinical Research at Palatin. The poster can be found on Palatin's website www.palatin.com.

Key Points: 
  • In preclinical studies in rat models of ulcerative colitis, oral PL8177 was found to be efficacious in reducing colonic damage and inflammation.
  • Clinical data presented in the poster shows that oral PL8177 was released in the GI tract and did not reach systemic circulation.
  • "We are looking forward to the data from an ongoing phase 2 study and the potential of PL8177 as a novel treatment for inflammatory bowel disease."
  • Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

CinRx Portfolio Company CinDome Pharma Presents Encouraging Data on Deudomperidone (CIN-102) at 2023 Digestive Disease Week® Conference

Retrieved on: 
Monday, May 8, 2023

CinDome Pharma, a CinRx portfolio company, presented a poster at the 2023 Digestive Disease Week (DDW) Conference titled “Effect of Therapeutic and Supratherapeutic Doses of Deudomperidone (CIN-102) on Cardiac Repolarization in a Thorough QT (TQT) Study in Healthy Subjects.” The poster highlighted data evaluating deudomperidone, a modified formulation of domperidone, for the long-term treatment of gastroparesis.

Key Points: 
  • CinDome Pharma, a CinRx portfolio company, presented a poster at the 2023 Digestive Disease Week (DDW) Conference titled “Effect of Therapeutic and Supratherapeutic Doses of Deudomperidone (CIN-102) on Cardiac Repolarization in a Thorough QT (TQT) Study in Healthy Subjects.” The poster highlighted data evaluating deudomperidone, a modified formulation of domperidone, for the long-term treatment of gastroparesis.
  • The study presented at DDW assessed the effect of deudomperidone on electrocardiogram (ECG) parameters, including concentration-QTc (C-QTc) analysis.
  • The data demonstrated the potential of deudomperidone to decrease the risk of QT prolongation associated with the traditional formulation of domperidone.
  • Deudomperidone is being developed by CinDome as the first line therapy for chronic gastroparesis, which impacts an estimated 16 million people in the U.S.

Olympus Announces FDA Clearance of New Endoscopy System and Compatible Endoscopes

Retrieved on: 
Tuesday, May 2, 2023

CENTER VALLEY, Pa., May 2, 2023 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced today the FDA clearance of the new EVIS X1 endoscopy system, along with two compatible gastrointestinal endoscopes: the GIF-1100 gastrointestinal videoscope indicated for use within the upper digestive tract including the esophagus, stomach, and duodenum; and the CF-HQ1100DL/I colonovideoscope indicated for use within the lower digestive tract including the anus, rectum, sigmoid colon, colon, and ileocecal valve.i

Key Points: 
  • The EVIS X1 endoscopy system features three new enhancements designed to assist physicians in visualizing GI bleeds and anatomical structures.
  • The proven optical-digital technology NBI™ (Narrow Band Imaging™) technology continues to be featured in this next-generation endoscopy system.
  • The EVIS X1 Endoscopy System will be on display and demonstrated in Olympus Booth #3820 at the DDW (Digestive Diseases Week) meeting in Chicago, May 7-9.
  • Information about the EVIS X1 Endoscopy System will be available here: info.olympusamericamarketing.com/X1 .

CinRx’s CinDome Pharma to Present a Poster on Deudomperidone (CIN-102) at 2023 Digestive Disease Week® Conference

Retrieved on: 
Tuesday, May 2, 2023

CinDome Pharma, a CinRx portfolio company, will present a poster at the 2023 Digestive Disease Week (DDW) Conference, held May 6th – 9th in Chicago, Illinois.

Key Points: 
  • CinDome Pharma, a CinRx portfolio company, will present a poster at the 2023 Digestive Disease Week (DDW) Conference, held May 6th – 9th in Chicago, Illinois.
  • The poster, titled “Effect of Therapeutic and Supratherapeutic Doses of Deudomperidone (CIN-102) on Cardiac Repolarization in a Thorough QT (TQT) Study In Healthy Subjects” will highlight data on the promise of deudomperidone for the long-term management of gastroparesis.
  • Gastroparesis impacts an estimated 16 million people in the US and has suboptimal existing treatment options.
  • The meeting showcases more than 3,100 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology.

GI Alliance Announces ASGE Group Partnership

Retrieved on: 
Tuesday, May 2, 2023

DALLAS, May 2, 2023 /PRNewswire/ -- GI Alliance , the nation's premier gastroenterology management company, and the American Society for Gastrointestinal Endoscopy (ASGE) are pleased to announce a new group partnership where all providers of GI Alliance are ASGE members.

Key Points: 
  • DALLAS, May 2, 2023 /PRNewswire/ -- GI Alliance , the nation's premier gastroenterology management company, and the American Society for Gastrointestinal Endoscopy (ASGE) are pleased to announce a new group partnership where all providers of GI Alliance are ASGE members.
  • With the launch of this new institutional membership category, GI Alliance has become ASGE's first group member with the joint goal of advancing the practice of GI.
  • GI Alliance has been the leader in this evolution of private practice," says ASGE President Bret Petersen, MD, MASGE.
  • For more information about ASGE group membership, please contact Donald Palmisano, ASGE CEO at [email protected] .

EQS-News: Mainz Biomed to Participate in Digestive Disease Week 2023

Retrieved on: 
Monday, May 1, 2023

Largest international meeting of physicians, researchers, and academics covering gastroenterology, hepatology, endoscopy, and gastrointestinal surgery

Key Points: 
  • Largest international meeting of physicians, researchers, and academics covering gastroenterology, hepatology, endoscopy, and gastrointestinal surgery
    BERKELEY, US – MAINZ, Germany – May 1, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its participation in the annual Digestive Disease Week (DDW) conference being held this year May 6-9 in Chicago, IL.
  • DDW is the world’s premier meeting for digestive disease academic and industry professionals and throughout the Conference, members of Mainz Biomed’s executive team will be interacting with scientific and business leaders and will utilize the event to host a meeting of the Company’s Medical Advisory Board (MAB).
  • Results from eAArly DETECT are expected in mid-2023 and Mainz Biomed anticipates enrollment in ReconAAsense to commence in the second half of 2023.
  • DDW brings together over 10,000 physicians, researchers and industry professionals comprising the digestive disease community.

Mainz Biomed to Participate in Digestive Disease Week 2023

Retrieved on: 
Monday, May 1, 2023

BERKELEY, Calif. and MAINZ, Germany, May 01, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its participation in the annual Digestive Disease Week (DDW) conference being held this year May 6-9 in Chicago, IL.

Key Points: 
  • BERKELEY, Calif. and MAINZ, Germany, May 01, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its participation in the annual Digestive Disease Week (DDW) conference being held this year May 6-9 in Chicago, IL.
  • Results from both studies are expected in 2023 and Mainz Biomed anticipates enrollment in ReconAAsense to commence in mid-2023.
  • DDW brings together over 10,000 physicians, researchers and industry professionals comprising the digestive disease community.
  • The 2023 conference is an in-person and online meeting showcasing more than 3,100 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology.

Health Catalyst, GIQuIC Team Up to Power the Nation's Only Gastroenterology-Focused Clinical Registry

Retrieved on: 
Tuesday, March 14, 2023

As noted in Health Catalyst's Q4 2022 earnings call announcement, GIQuiC which offers the only national gastroenterology-focused clinical registry, will utilize ARMUS by Health Catalyst's HYBRID Clinical Registry and Reporting solution to advance the extraction process, including a streamlined user experience, enhanced data capture process, and improved reporting.

Key Points: 
  • As noted in Health Catalyst's Q4 2022 earnings call announcement, GIQuiC which offers the only national gastroenterology-focused clinical registry, will utilize ARMUS by Health Catalyst's HYBRID Clinical Registry and Reporting solution to advance the extraction process, including a streamlined user experience, enhanced data capture process, and improved reporting.
  • "This collaboration will enhance the service we already provide to our registry participants by allowing GIQuIC to leverage the depth and breadth of offerings and prior experience and success Health Catalyst has with respect to registry services and healthcare analytics.
  • "Data abstraction and registry reporting are critical functions of healthcare organizations, and we are delighted GIQuIC has selected Health Catalyst to power this important work," said Dan Burton, CEO of Health Catalyst.
  • "We look forward to an enduring partnership with the GIQuIC team and registry participants."